1. 2602 Pazopanib (Pz) as first line for metastatic renal carcinoma (mRC): Updated validation of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model (IMRCC). The SPAZO study (SOGUG). (September 2015) Authors: Perez-Valderrama, B.; Arija, J.A. Arranz; Vidal, M.J. Méndez; Carbonero, I. García; Rodríguez, C. Suárez; Gallego, P. Jiménez; López-Brea, M.; Marrero, R.D. García; García, J.A. Meana; Gajate, P.; Santander, C.; Palau, C. Molins; Parra, E.M. Fernández; Torras, O. Reig; Basterrechea, L.; Estévez, ... Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S512 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗